Skip to main content Skip to main navigation menu Skip to site footer
International Journal of Nutrology
Articles
DOI: 10.1055/s-0040-1705286
Submitted: 02-13-2022
Published: 02-13-2022

Bariatric surgery in HIV-infected patients: review of literature

SAE Barueri e PortoMed Assistência Médica, Brazil
HIV obesity bariatric surgery

Abstract

Obesity is now a common problem among HIV-infected patients receiving antiretroviral therapy (ART). Until recently, HIV infection has been considered a contraindication to bariatric surgery for various reasons. Insurance carriers have considered HIV a terminal disease, and surgeons have been reluctant to operate HIV-infected patients because of this, as well as the associated risk of infectious transmissions, although this has been changing. Gastric bypass surgery may be an option for some patients who have failed diet and therapeutic lifestyle changes, modification in ART or other treatment modalities for HIV/ART-related lipohypertrophy and obesity. However, few data are available regarding HIV-related outcomes after such surgery and its impact on ART tolerability. The aim of this study is to review bariatric surgery in HIV-infected patients.

Metrics

Metrics Loading ...

References

  1. UNAIDS report on the global AIDS epidemic 2016. [cited 11 July 2016]; Available from: http://www.unaids.org/en/resources/documents/2016/AIDS-by-the-numbers
  2. Boletim Epidemiológico HIV/aids. Ministério da Saúde, Distrito Federal 2015. Ano IV número 01.
  3. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279:450-4.
  4. Palella, FJ Jr, Delaney, KM, Moorman, AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853– 60.
  5. Enanoria WTA, Ng C, Saha SR, et al. Treatment outcomes after highly active antiretroviral therapy: A meta-analysis of randomized controlled trials. Lancet Infect Dis 2004; 4:414 -25.
  6. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27–34.
  7. Weber R, Ruppik M, Rickenbach M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013; 14:195–207.
  8. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51– 8.
  9. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired glucose tolerance in HIV-1–infected patients. AIDS 1998; 12:F167–74.
  10. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV protease inhibitor–associated lipodystrophy, hyperlipidaemia, and diabetes mellitus. Lancet 1999; 353:2893–9.
  11. Saint-Marc T, Partisani M, Poizor-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13:1359–67.
  12. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351(9112):1328.
  13. Flynn TE, Briscker LA. Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann Intern Med 1999; 131:258.
  14. Poirier P, Cornier MA, Mazzone T, et al. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation 2011; 123:1683-701.
  15. Global Health Observatory (GHO): Obesity. World Health Organisation, editor. 7-4-2014. Available at: http://www.who.int/gho/ncd/risk_ factors/bmi_text/en/. Accessed January 9, 2015.
  16. Sturm R. Increases in morbid obesity in the USA: 2000-2005. Public Health 2007; 121:492-6.
  17. Mathieu P, Poirier P, Pibarot P, Lemieux I, Despres JP. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension 2009; 53:577-84.
  18. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006;113: 898-918.
  19. Tang, AM., Jacobson, DL., Spiegelman, D., Knox, TA., & Wanke, C. Increasing risk of 5% or greater unintentional weight loss in a cohort of HIV-infected patients, 1995 to 2003. J Acquir Immune Defic Syndr 2005; 40, 70-76.
  20. Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholhm, D., et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 14, F25-F32.
  21. Heath, K. V., Hogg, R. S., Singer, J., Chan, K. J., O’Shaughnessy, M. W., & Montaner, J. S. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort. J Acquir Immune Defic Syndr 2002; 30: 440-447.
  22. Ogden, C. L., Carroll, M. D., Curtin, L. R., McDowell, M. A., Tabak, C. J., & Flegal, K. M. Prevalence of overweight and obesity in the United States, 1999-2004. J Am Med Assoc, 2006; 295: 1549-1555.
  23. Grundy, S. M., Brewer, H. B., Jr., Cleeman, J. I., Smith, S. C., Jr., & Lenfant, C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004; 109: 433-438.
  24. Thompson-Paul AM1, Wei SC, Mattson CL, Robertson M, Hernandez-Romieu AC, Bell TK et al. Obesity Among HIV-Infected Adults Receiving Medical Care in the United States: Data From the Cross-Sectional Medical Monitoring Project and National Health and Nutrition Examination Survey. Medicine (Baltimore) 2015; 94(27):1-10.
  25. Keithley JK, Duloy AM, Swanson B, et al. HIV infection and obesity: a review of the evidence. J Assoc Nurses in AIDS Care: JANAC 2009; 20(4):260–74.
  26. Hsue P, Hunt P, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIVassociated atherosclerosis. AIDS 2009; 23:1059–1067.
  27. Boccara F. Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: Type, incidence and associated risk factors. AIDS 2008; 22 (Suppl 3): S19–S26.
  28. Miller M, Kahraman A, Ross B, et al. Evaluation of quantitative liver function tests in HIV-positive patients under anti-retroviral therapy. Eur J Med Res 2009; 14(9):369–77.
  29. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007; 357(8):753–61.
  30. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K et al. Bariatric surgery: a systematic review and meta analysis. JAMA 2004; 292(14):1724–37.
  31. Sjostrom L, Lindross A, Peltonen, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351:2683–2693.
  32. Sjostrom L, Narbro K, Sjostrom D, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357:741–752.
  33. Adams T, Gress R, Smith S, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007; 357:753–761.
  34. The Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Perioperative Safety in the Longitudinal Assessment of Bariatric Surgery. N Engl J Med 2009; 361:445–454.
  35. Jensen MD, Ryan DH, Donato KA, et al. Executive summary: guidelines (2013) for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society Published by The Obesity Society and American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Based on a systematic review from The Obesity Expert Panel, 2013. Obesity (Silver Spring) 2014; 22(suppl 2):S5-39.
  36. Keithley JK, Duloy MAS, Swanson B,Zeller JM. HIV Infection and Obesity: A Review of the Evidence. Journal of the Association of Nurses in AIDS Care 2009; 20(4):260-274
  37. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2013; 36:S11-66.
  38. Dixon JB, Zimmet P, Alberti KG, Rubino F. Bariatric surgery: an IDF statement for obese type 2 diabetes. Diabet Med 2011; 28:628-42.
  39. Rubino F, Kaplan LM, Schauer PR, Cummings DE. The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg 2010; 251:399-405.
  40. Brolin RE. Update: NIH consensus conference. Gastrointestinal surgery for severe obesity. Nutrition 1996; 12:403-4.
  41. Mechanick JI, Youdim A, Jones DB, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patiente2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic and Bariatric Surgery. Endocr Pract 2013; 19:337-72.
  42. Flum DR, Belle SH, King WC, et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009;361: 445-54.
  43. Poirier P, Alpert MA, Fleisher LA, et al. Cardiovascular evaluation and management of severely obese patients undergoing surgery: a Science advisory from the American Heart Association. Circulation 2009;120: 86-95.
  44. Lavie CJ, McAuley PA, Church TS, Milani RV, Blair SN. Obesity and cardiovascular diseases: implications regarding fitness, fatness, and severity in the obesity paradox. J Am Coll Cardiol 2014; 63:1345-54.
  45. Fisher BL, Schauer P. Medical and surgical options in the treatment of severe obesity. Am J Surg 2002;184(6B):9S-16S.
  46. Karmali S, Schauer P, Birch D, Sharma AM, Sherman V. Laparoscopic sleeve gastrectomy: an innovative new tool in the battle against the obesity epidemic in Canada. Can J Surg 2010; 53:126-32.
  47. Buchwald H, Oien DM. Metabolic/bariatric surgery Worl-dwide 2008. Obes Surg 2009; 19:1605-11.
  48. Scopinaro N, Gianetta E, Civalleri D, Bonalumi U, Bachi V. Biliopancreatic bypass for obesity: II. Initial experience in man. Br J Surg 1979; 66:618-20.
  49. Hess DS, Hess DW. Biliopancreatic diversion with a duodenal switch. Obes Surg 1998; 8:267-82.
  50. Marceau P, Hould FS, Potvin M, Lebel S, Biron S. Biliopancreatic diversion (doudenal switch procedure). Eur J Gastroenterol Hepatol 1999; 11:99-103.
  51. Flancbaum L, Drake V, Colarusso T, et al. Initial experience with bariatric surgery in asymptomatic human immunodeficiency virus-infected patients. Surg Obes Relat Dis 2005: 1:73–76.
  52. Fazylov R, Soto E, Merola S. Laparoscopic gastric by-pass surgery in human immunodeficiency virus-infected patients. Surg Obes Relat Dis 2007; 3:637–639.
  53. Selke H, Norris S, Osterholzer D, Kenneth, Fife KH, DeRose B, Gupta SK. AIDS Patient Care and STDs 2010; 24(9): 545-550.
  54. Fysekidis M, Cohen R, Bekheit M, Chebib J, Boussairi A, Bihan H et al.Sleeve gastrectomy is a safe and efficient procedure in HIV patients with morbid obesity: a case series with results in weight loss, comorbidity evolution, CD4 count, and viral load. Obes Surg 2015; 25:229–233.
  55. Eddy F, Elvin S, Sanmani L. Bariatric Surgery: An HIV-positive patient’s successful journey. Int J STD AIDS. 2015 doi:10.1177/0956462415571971.
  56. Pourcher G, Costagliola D, Martinez V, Obesity in HIV-infected patients in France: Prevalence and surgical treatment options. Journal of Visceral Surgery 2015; 9:633-35. 153:32-37.
  57. Zivich S, Cauterucci M, Allen S, Vetter M. Long-term virologic outcomes following bariatric surgery in patients with HIV. Obes Res Clin Pract 2015;
  58. Sardo P, Walker JH. Bariatric surgery: impact on medication management. Hosp Pharm 2008; 43(2):113–20.
  59. Brocks DR, Ben-Eltriki M, Gabr RQ, et al. The effects of gastric bypass surgery on drug absorption and pharmacokinetics. Expert Opin Drug Metab Toxicol 2012; 8(12):1505–19.
  60. Michalaki MA, Gkotsina MI, Mamali I, et al. Impaired pharmacokinetics of levothyroxine in severely obese volunteers. Thyroid: Off J Am Thyroid Assoc 2011; 21(5):477–81.
  61. Kamimura M, Watanabe K, Kobayakawa M, et al. Successful absorption of antiretroviral drugs after gastrojejunal bypass surgery following failure of therapy through a jejunal tube. Intern Med 2009; 48(12):1103–4.
  62. Boffito M, Lucchini A, Maiello A, et al. Lopinavir/ritonavir Absorption in gastrectomized patient. AIDS 2003; 17:136-137

How to Cite

Silva, E. F. R. da. (2022). Bariatric surgery in HIV-infected patients: review of literature. International Journal of Nutrology, 10(2), 28–36. https://doi.org/10.1055/s-0040-1705286